Cargando…

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation

The kinetics of early and late cytomegalovirus (CMV) reactivation after hematopoietic cell transplantation using various methods of graft-versus-host-disease (GVHD) prophylaxis are poorly defined. We retrospectively compared CMV reactivation and disease among 780 seropositive patients given HLA-matc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueda Oshima, Masumi, Xie, Hu, Zamora, Danniel, Flowers, Mary E., Hill, Geoffrey R., Mielcarek, Marco B., Sandmaier, Brenda M., Gooley, Ted A., Boeckh, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139935/ https://www.ncbi.nlm.nih.gov/pubmed/36595478 http://dx.doi.org/10.1182/bloodadvances.2022009112

Ejemplares similares

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

2109. HHV-6 and EBV Reactivation after Allogeneic Hematopoietic Cell Transplantation in the Era of Letermovir for CMV Prophylaxis: A Retrospective Cohort Study
por: Kampouri, Eleftheria, et al.
Publicado: (2022)

Risk factors for seasonal human coronavirus lower respiratory tract infection after hematopoietic cell transplantation
por: Ogimi, Chikara, et al.
Publicado: (2021)

T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity
por: Lum, Su Han, et al.
Publicado: (2022)

HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age
por: Ambinder, Alexander, et al.
Publicado: (2022)

491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

194. Combinatorial Polyfunctionality Analysis of Antigen-specific T-cell Subsets (COMPASS) as a Predictor for Clinically Significant CMV Infection in the Letermovir Era
por: Zamora, Danniel, et al.
Publicado: (2020)

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
por: Akahoshi, Yu, et al.
Publicado: (2023)

Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies
por: Fatobene, Giancarlo, et al.
Publicado: (2023)

Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD
por: Bruce, Danny W., et al.
Publicado: (2021)

Megadose (90)Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
por: Chow, Victor A., et al.
Publicado: (2021)

Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
por: Vasu, Sumithira, et al.
Publicado: (2022)

ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD
por: Xiao, Zunyu, et al.
Publicado: (2022)

Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant
por: Wu, Natalie L., et al.
Publicado: (2022)

Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice
por: Adams, Rachael C., et al.
Publicado: (2022)

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice
por: Wu, Yongxia, et al.
Publicado: (2022)

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
por: Yu, Xiaoliang, et al.
Publicado: (2023)

Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice
por: Zhang, Xin, et al.
Publicado: (2023)

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD
por: Bethge, Wolfgang, et al.
Publicado: (2014)

Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG
por: Turki, Amin T., et al.
Publicado: (2021)

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2023)

2591. The Role of Neutralizing Antibodies (nAb) Against Cytomegalovirus (CMV) Epithelial Cell-entry in Patients with Self-limited (SL) CMV infection after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2019)

Single-cell immune profiling reveals a developmentally distinct CD4(+) GM-CSF(+) T-cell lineage that induces GI tract GVHD
por: Piper, Clint, et al.
Publicado: (2022)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation
por: Sajulga, Ray, et al.
Publicado: (2022)

Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB
por: Clerici, Daniela, et al.
Publicado: (2022)

Assessment of HLA-DPB1 genetic variation using an HLA-DP tool and its implications in clinical transplantation
por: Sajulga, Ray, et al.
Publicado: (2023)

Prediction of outcomes after second-line treatment for acute graft-versus-host disease
por: Vo, Phuong, et al.
Publicado: (2022)

Emergence of human CMV-induced NKG2C(+) NK cells is associated with CD8(+) T-cell recovery after allogeneic HCT
por: van der Ploeg, Kattria, et al.
Publicado: (2023)

Time to Move on: HLA Matching Should Be Reconsidered in Modern Deceased Donor Kidney Allocation
por: Gramlick, Madelyn E., et al.
Publicado: (2022)

Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation
por: Petersdorf, Effie W., et al.
Publicado: (2023)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_652l5jnedt4ed38sudigv2s44s